1. Home
  2. XFOR vs SRBK Comparison

XFOR vs SRBK Comparison

Compare XFOR & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • SRBK
  • Stock Information
  • Founded
  • XFOR 2014
  • SRBK 1887
  • Country
  • XFOR United States
  • SRBK United States
  • Employees
  • XFOR N/A
  • SRBK N/A
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • SRBK
  • Sector
  • XFOR Health Care
  • SRBK
  • Exchange
  • XFOR Nasdaq
  • SRBK Nasdaq
  • Market Cap
  • XFOR 118.4M
  • SRBK 117.4M
  • IPO Year
  • XFOR N/A
  • SRBK N/A
  • Fundamental
  • Price
  • XFOR $1.61
  • SRBK $14.03
  • Analyst Decision
  • XFOR Strong Buy
  • SRBK
  • Analyst Count
  • XFOR 3
  • SRBK 0
  • Target Price
  • XFOR $72.33
  • SRBK N/A
  • AVG Volume (30 Days)
  • XFOR 1.8M
  • SRBK 47.9K
  • Earning Date
  • XFOR 08-11-2025
  • SRBK 07-31-2025
  • Dividend Yield
  • XFOR N/A
  • SRBK 1.42%
  • EPS Growth
  • XFOR N/A
  • SRBK N/A
  • EPS
  • XFOR 2.16
  • SRBK 0.44
  • Revenue
  • XFOR $31,364,000.00
  • SRBK $31,833,000.00
  • Revenue This Year
  • XFOR $1,300.08
  • SRBK N/A
  • Revenue Next Year
  • XFOR N/A
  • SRBK N/A
  • P/E Ratio
  • XFOR $0.74
  • SRBK $31.89
  • Revenue Growth
  • XFOR N/A
  • SRBK 39.53
  • 52 Week Low
  • XFOR $1.38
  • SRBK $9.50
  • 52 Week High
  • XFOR $26.83
  • SRBK $14.96
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 40.77
  • SRBK 50.34
  • Support Level
  • XFOR $1.55
  • SRBK $13.55
  • Resistance Level
  • XFOR $2.22
  • SRBK $14.14
  • Average True Range (ATR)
  • XFOR 0.20
  • SRBK 0.27
  • MACD
  • XFOR 0.06
  • SRBK -0.10
  • Stochastic Oscillator
  • XFOR 26.44
  • SRBK 43.44

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About SRBK SR Bancorp Inc. Common stock

SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.

Share on Social Networks: